Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212883988> ?p ?o ?g. }
- W3212883988 abstract "This study explored the roles of activins and follistatin in colorectal cancers. Paired malignant and normal colonic tissues were collected from archived paraffin-embedded (n = 90 patients) alongside fresh (n = 40 patients) specimen cohorts. Activin β-subunits, follistatin and Smad4 mRNAs and proteins were measured by real-time PCR and immunohistochemistry (IHC). Mature activin-A, -B, -AB and follistatin proteins were measured by ELISA. Cancer tissues having ≤ the 20th percentile of the Smad4 IHC score were considered as low (L-S4) group. The Smad4-intact SW480 and Smad4-null HT29 colon cancer cell lines were treated with activins and follistatin, and cell cycle was analysed by flow cytometry. The cell cycle inducing (CCND1/CCND3) and inhibitory (p21/p27) proteins alongside the survival (survivin/BCL2) and pro-apoptosis (Casp-8/Casp-3) markers were measured by immunofluorescence. Thirty-nine patients had right-sided cancers (30%) and showed higher rates of L-S4 tumours (n = 17; 13.1%) alongside worse clinicopathological characteristics relative to left-sided cancers. The βA-subunit and activin-A increased, whilst βB-subunit and activin-AB decreased, in malignant sites and the late-stage cancers revealed the greatest abnormalities. Interestingly, follistatin declined markedly in early-stage malignant tissues, whilst increased significantly in the advanced stages. All activin molecules were comparable between the early stage right- and left-sided tumours, whereas the late-stage right-sided cancers and L-S4 tumours showed more profound deregulations. In vitro, activin-A increased the numbers of the SW480 cells in sub-G1 and G0/G1-phases, whereas reduced the HT29 cell numbers in the sub-G1 phase with simultaneous increases in the G0/G1 and S phases. The p21/p27/Casp-8/Casp-3 proteins escalated, whilst CCND1/CCND3/BCL2/survivin declined in the SW480 cells following activin-A, whereas activin-A only promoted p21 and p27 alongside reduced CCND3 in the HT29 cells. By contrast, activin-AB increased the numbers of SW480 and HT29 cells in Sub-G1 and G0/G1-phases and promoted the anti-cancer and reduced the oncogenic proteins in both cell lines. In conclusion, activins and follistatin displayed stage-dependent dysregulations and were markedly altered during the advanced stages of right-sided and L-S4 cancers. Moreover, the activin-A actions in CRC could be Smad4-dependent, whereas activin-AB may act as a Smad4-independent tumour suppressor protein." @default.
- W3212883988 created "2021-11-22" @default.
- W3212883988 creator A5004734725 @default.
- W3212883988 creator A5017880181 @default.
- W3212883988 creator A5020849088 @default.
- W3212883988 creator A5022477056 @default.
- W3212883988 creator A5031575784 @default.
- W3212883988 creator A5045310876 @default.
- W3212883988 creator A5051675043 @default.
- W3212883988 creator A5061395047 @default.
- W3212883988 creator A5066829700 @default.
- W3212883988 creator A5077010147 @default.
- W3212883988 creator A5085692703 @default.
- W3212883988 creator A5087399160 @default.
- W3212883988 creator A5087908641 @default.
- W3212883988 creator A5089565677 @default.
- W3212883988 creator A5091220099 @default.
- W3212883988 date "2021-11-15" @default.
- W3212883988 modified "2023-09-29" @default.
- W3212883988 title "Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status" @default.
- W3212883988 cites W1579738710 @default.
- W3212883988 cites W1964325422 @default.
- W3212883988 cites W1965190528 @default.
- W3212883988 cites W1977151351 @default.
- W3212883988 cites W1995140691 @default.
- W3212883988 cites W1995383756 @default.
- W3212883988 cites W2016068055 @default.
- W3212883988 cites W2018385095 @default.
- W3212883988 cites W2033700197 @default.
- W3212883988 cites W2038155245 @default.
- W3212883988 cites W2041391374 @default.
- W3212883988 cites W2053935936 @default.
- W3212883988 cites W2054322693 @default.
- W3212883988 cites W2058208039 @default.
- W3212883988 cites W2085755944 @default.
- W3212883988 cites W2086838915 @default.
- W3212883988 cites W2097924745 @default.
- W3212883988 cites W2126762584 @default.
- W3212883988 cites W2153611576 @default.
- W3212883988 cites W2155229125 @default.
- W3212883988 cites W2155358741 @default.
- W3212883988 cites W2159824199 @default.
- W3212883988 cites W2160096184 @default.
- W3212883988 cites W2231572828 @default.
- W3212883988 cites W2238874802 @default.
- W3212883988 cites W2407141675 @default.
- W3212883988 cites W2464706565 @default.
- W3212883988 cites W2543412381 @default.
- W3212883988 cites W2546219240 @default.
- W3212883988 cites W2556184537 @default.
- W3212883988 cites W2557927385 @default.
- W3212883988 cites W2724306819 @default.
- W3212883988 cites W2735265983 @default.
- W3212883988 cites W2735619199 @default.
- W3212883988 cites W2792793299 @default.
- W3212883988 cites W2797653557 @default.
- W3212883988 cites W2800852215 @default.
- W3212883988 cites W2805133572 @default.
- W3212883988 cites W2866982694 @default.
- W3212883988 cites W2889646458 @default.
- W3212883988 cites W2897595058 @default.
- W3212883988 cites W2910178612 @default.
- W3212883988 cites W2913758411 @default.
- W3212883988 cites W2920813333 @default.
- W3212883988 cites W2943961082 @default.
- W3212883988 cites W2944356931 @default.
- W3212883988 cites W2969665263 @default.
- W3212883988 cites W2972383021 @default.
- W3212883988 cites W2981619247 @default.
- W3212883988 cites W3007730630 @default.
- W3212883988 cites W3014008006 @default.
- W3212883988 cites W3015966544 @default.
- W3212883988 cites W3110973817 @default.
- W3212883988 cites W3142607725 @default.
- W3212883988 cites W2189082525 @default.
- W3212883988 doi "https://doi.org/10.3389/pore.2021.1610032" @default.
- W3212883988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34867090" @default.
- W3212883988 hasPublicationYear "2021" @default.
- W3212883988 type Work @default.
- W3212883988 sameAs 3212883988 @default.
- W3212883988 citedByCount "5" @default.
- W3212883988 countsByYear W32128839882022 @default.
- W3212883988 countsByYear W32128839882023 @default.
- W3212883988 crossrefType "journal-article" @default.
- W3212883988 hasAuthorship W3212883988A5004734725 @default.
- W3212883988 hasAuthorship W3212883988A5017880181 @default.
- W3212883988 hasAuthorship W3212883988A5020849088 @default.
- W3212883988 hasAuthorship W3212883988A5022477056 @default.
- W3212883988 hasAuthorship W3212883988A5031575784 @default.
- W3212883988 hasAuthorship W3212883988A5045310876 @default.
- W3212883988 hasAuthorship W3212883988A5051675043 @default.
- W3212883988 hasAuthorship W3212883988A5061395047 @default.
- W3212883988 hasAuthorship W3212883988A5066829700 @default.
- W3212883988 hasAuthorship W3212883988A5077010147 @default.
- W3212883988 hasAuthorship W3212883988A5085692703 @default.
- W3212883988 hasAuthorship W3212883988A5087399160 @default.
- W3212883988 hasAuthorship W3212883988A5087908641 @default.
- W3212883988 hasAuthorship W3212883988A5089565677 @default.
- W3212883988 hasAuthorship W3212883988A5091220099 @default.
- W3212883988 hasBestOaLocation W32128839881 @default.